Major Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment
Discover the latest drugs and treatment options in the Major Depressive Disorder Pipeline. Dive into DelveInsight's comprehensive report today! @ Major Depressive Disorder Pipeline Outlook
Key Takeaways from the Major Depressive Disorder Pipeline Report
In May 2025, Biohaven Therapeutics Ltd announced a study to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD).
In May 2025, Neurocrine Biosciences conducted a study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
In May 2025, Neumora Therapeutics, Inc. organized a study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).
In May 2025, Otsuka Pharmaceutical Development & Commercialization, Inc. announced a phase 2 study parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD).
In May 2025, Janssen Research & Development LLC announced a study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
DelveInsight's Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.
The leading Major Depressive Disorder Companies such as GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
Promising Major Depressive Disorder Pipeline Therapies such as NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others.
Stay ahead with the most recent pipeline outlook for Major Depressive Disorder. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Major Depressive Disorder Medication
Major Depressive Disorder Emerging Drugs Profile
SAGE-217: Sage Therapeutics
SAGE-217 is an investigational, oral, novel medicine in development for depression. SAGE-217 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. Biogen and Sage Therapeutics have submitted a new drug application (NDA) to the FDA for zuranolone for the treatment of major depressive disorder (MDD).
REL-1017: Relmada Therapeutics Inc.
REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD.
Seltorexant: Minerva Sciences
Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.
SP-624: Sirtsei Pharmaceuticals, Inc.
SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc.
SPL026: Small Pharma
SPL026 (DMT), is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world's first DMT clinical trial for depression, in collaboration with Imperial College London.
PDC-1421: BioLite Inc.
PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development.
The Major Depressive Disorder Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Major Depressive Disorder with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder Medication.
Major Depressive Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Major Depressive Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Major Depressive Disorder market
Explore groundbreaking therapies and clinical trials in the Major Depressive Disorder Medication. Access DelveInsight's detailed report now! @ New Major Depressive Disorder Drugs
Major Depressive Disorder Companies
GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Subcutaneous
Intravenous
Intramuscular
Major Depressive Disorder Products have been categorized under various Molecule types such as
Bispecific Antibody
Peptides
Small molecule
Gene therapy
Unveil the future of Major Depressive Disorder Medication. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Major Depressive Disorder Market Drivers and Barriers
Scope of the Major Depressive Disorder Pipeline Report
Coverage- Global
Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
Major Depressive Disorder Pipeline Therapies- NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others.
Major Depressive Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Major Depressive Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Major Depressive Disorder Medication and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Major Depressive Disorder Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Major Depressive Disorder: Overview
Pipeline Therapeutics
Therapeutic Assessment
Major Depressive Disorder – DelveInsight's Analytical Perspective
Late Stage Products (Preregistration)
SAGE-217: Sage Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
SP-624: Sirtsei Pharmaceuticals, Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SPL026: Small Pharma
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug Name: Company name
Drug profiles in the detailed report…..
Inactive Products
Major Depressive Disorder Key Companies
Major Depressive Disorder Key Products
Major Depressive Disorder- Unmet Needs
Major Depressive Disorder- Market Drivers and Barriers
Major Depressive Disorder- Future Perspectives and Conclusion
Major Depressive Disorder Analyst Views
Major Depressive Disorder Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/major-depressive-disorder-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
30 minutes ago
- CTV News
Quebec wants to cut by 10% premature deaths linked to social, economic status
Quebec Health Minister Christian Dubé speaks at a legislature committee at the legislature in Quebec City, Tuesday, May 27, 2025. THE CANADIAN PRESS/Jacques Boissinot Quebec's Health Department has released a plan to reduce premature deaths linked to social and economic inequalities by 10 per cent by 2035. The province defines premature deaths as those before age 75 caused by conditions such as cardiovascular disease, diabetes, and cancer. Health officials say these early deaths are often preventable and more frequent among low-income people and those who are vulnerable and marginalized. The province says it will invest $15 million in the first year of the plan for chronic disease screening for such things as HPV, Type 2 diabetes and cardiovascular risk. The government is also aiming to improve people's access to physical activities. As well, the province plans to spend $4 million on programs to help people quit smoking. This report by The Canadian Press was first published Aug. 21, 2025.
National Post
30 minutes ago
- National Post
Randall Denley: I thought Ford wasn't serious about solving the doctor shortage. I was wrong
Ontario's shortage of family doctors has received a lot of media and public attention, but Premier Doug Ford's increasingly credible effort to fix the problem is mostly flying under the radar. Article content Back in January, the government announced it would spend $1.8 billion over four years to provide family doctors for two million Ontarians who don't have one. At the time, it sounded more like a placeholder than a real plan. It was something simple for PC candidates to say when voters asked them about the long-standing doctor shortage during the snap election scheduled for the following month. Article content Article content Article content The government's claim that it could expand primary care coverage to include more than 300,000 people in 2025-26 didn't seem credible given the many stories of burned-out family doctors facing the high cost of running a practice, low pay and the burden of unpaid paperwork. Many were reportedly disillusioned by years of successive governments failing to take the problem seriously. Article content Article content The impression was one of a primary care system struggling to maintain current service levels and incapable of doing more. In the face of all of that, the government said it would simply ask for proposals to create new medical clinics or expand existing ones to handle more patients. Article content The response has been surprisingly robust. In June, the government announced that it had approved 130 proposals for expansion, enough to meet its first-year target of serving 300,000 additional patients. That was an encouraging start, although the targets for the remaining three years are much higher, with 500,000 the goal for next year and 600,000 for each of the two years after that. Article content Article content Despite the strong beginning, one had to wonder what would drive the continued expansion, given all the known negatives. Then, earlier this month, news came of a deal that will almost certainly be a game changer for primary care and Ontario patients. Article content Last fall, the provincial government and the Ontario Medical Association (OMA) reached an arbitrated settlement that provided a big pay increase for doctors, nearly 10 per cent in the first year. What was unclear was how higher pay would translate into increased primary care capacity. Article content Negotiations between the province and the OMA have continued and at last, the government is listening to family doctors and addressing their concerns in a way that will encourage doctors to enter family practice. Article content The doctors and the government have nearly finalized a comprehensive plan to make family practice much more financially attractive. Among the changes are payment for administrative work, higher payments for services provided, after-hours premiums and financial incentives to add new patients. Article content With all the new incentives combined, the government says Ontario's family doctors will be the best paid in the country. The administrative fee alone is substantial. The average family physician does about 20 hours a week of administrative work, which will now be compensated at $80 an hour. Article content The negotiations on the enhancement deal aren't yet complete, but the OMA says the new approach will help attract and retain family doctors. Article content Dr. David Barber, chair of the OMA's family medicine section, says 'The model introduces meaningful investments, improved revenue streams, and long-overdue recognition for the time we spend on both clinical and non-clinical care. Importantly, it also opens additional space for physicians to join FHOs, broadening access to comprehensive primary care across Ontario.' Article content The FHOs, or family health organizations, that Barber refers to are the key to the government's new approach. They are primary care teams that can include doctors, registered nurses, physiotherapists, social workers and pharmacists. It's a smart approach that lets patients get a variety of services at one location. Article content Article content About 6,500 of the province's 17,000 family physicians work in FHOs, but the new money will certainly boost that number. Article content The Ford government has done the right thing in offering family physicians incentives to do more and increasing their pay so family practice can compete with other medical specialties. That, combined with expanded training positions for family doctors, constitutes a rational approach to a critical labour shortage. Article content That's almost shocking in a socialized medicine system that is usually all about limiting spending and rationing care. Perhaps politicians have finally realized that it's a rare person who would say, 'I don't need a family doctor. I want government spending restraint instead.' Article content The Ford government still has a long way to go to meet the need for primary care, but it has finally created a structure that seems likely to succeed. It won't be cheap. With additional budget money added this year, the four-year expansion cost is now $2.1 billion, but at least it's spending aimed at measurable and necessary results.
CBC
32 minutes ago
- CBC
Quebec kids' helpline scales back in-school activities as pandemic funding ends
Social Sharing After expanding its services in recent years to address the growing distress of youth in Quebec, Tel-jeunes said funding issues are forcing it to cut some of its programs, including in-school workshops and a chat service for teens, by teens. The organization, which provides listening and psychosocial intervention services for youth, said it received emergency funding from the Education Ministry to the tune of $8 million over four years for special projects during the COVID-19 pandemic. The peer-to-peer chat service was one of the services Tel-jeunes put in place to help teens cope during the health crisis. "We had teens, aged 17 to 19, that worked with us at Tel-jeunes, who would respond to teens who contacted us with their concerns," said executive director Annie Papageorgiou. When the pandemic ended, however, so too did the additional funding. Tel-jeunes said it applied for a grant for the 2024-25 school year, but learned from the Education Ministry in December that it hadn't been selected. That was around the same time the organization was sounding the alarm over rising mental health calls to its kids' helpline, which runs seven days a week. The phone service helped 30,000 young people in 2024, with Papageorgiou telling CBC in an interview at the time that 15 per cent of them had suicidal thoughts — twice as many as in 2019, before the pandemic. Without additional resources, Papageorgiou said the organization had to focus on maintaining its essential or front-line services. The decision to end certain programs was "difficult" and "heartbreaking," Papageorgiou said, because in addition to layoffs, it also means reduced support for young people in need. Teachers aren't mental health specialists That is also a concern for school administrators, who are calling on the government to reverse course. "Students have had a tough time coming back to school after the pandemic and they still have impacts of that and it shows," said André Bernier, president of the Association québécoise du personnel de direction d'école — an association representing more than 800 school administrators in the province. Bernier said Tel-jeunes's workshops in schools, which reached 15,000 students last year, touched on mental health and other topics and while teachers know about the issues, they aren't specialists in those fields. "They don't know enough to go as far as Tel-jeunes could go when they were coming to schools," he said. "And that's a big impact." In a statement, a spokesperson for the Education Ministry says it didn't terminate any funding agreements, but prioritized organizations in more precarious financial positions than Tel-jeunes. The ministry said its decision doesn't reflect on the important services Tel-jeunes offers.
